Huilun Pharmaceutical Overview
- Year Founded
-
2004
- Status
-
IPO Registration
- Employees
-
1,420
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
12
Huilun Pharmaceutical General Information
Description
Developer and manufacturer of innovative pharmaceutical products designed for oncology, immunology, inflammation, pain management, and chronic disease treatments. The company provides a portfolio of proprietary Class I innovative drugs, improved formulations, and first-generic medicines, enabling healthcare providers and patients with safe, effective, and high-clinical-value therapies that address unmet medical needs.
Contact Information
Website
www.huilun.comCorporate Office
- Room 1001-1002, Phase II, Greenland Center
- No. 562 Dong'an Road, Xuhui District
- Shanghai, 200241
- China
Corporate Office
- Room 1001-1002, Phase II, Greenland Center
- No. 562 Dong'an Road, Xuhui District
- Shanghai, 200241
- China
Huilun Pharmaceutical Timeline
Huilun Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. IPO | 02-Apr-2026 | Announced | Generating Revenue | |||
| 13. Later Stage VC (Series I) | 22-Aug-2025 | Completed | Generating Revenue | |||
| 12. Secondary Transaction - Private | 21-Aug-2025 | Completed | Generating Revenue | |||
| 11. Secondary Transaction - Private | 01-Oct-2024 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series H) | 21-Oct-2024 | Completed | Generating Revenue | |||
| 9. Merger/Acquisition | 23-Feb-2024 | Cancelled | Generating Revenue | |||
| 8. Later Stage VC (Series G) | 28-Nov-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series F) | 15-Dec-2021 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 01-Nov-2021 | $139M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series E) | 01-Apr-2021 | $52.9M | $139M | Completed | Generating Revenue |
Huilun Pharmaceutical Patents
Huilun Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026189513-A1 | Pharmaceutical salt of sulfonamide compound, crystal form of salt, composition, and use | Pending | 14-Mar-2025 | ||
| EP-4837908-A1 | Novel sodium channel modulator compound and use thereof | Pending | 23-Jan-2025 | ||
| WO-2026139098-A1 | Pharmaceutical combination and use thereof in treatment of acne | Pending | 26-Dec-2024 | ||
| WO-2026109030-A1 | Piperidine ring compound, pharmaceutical composition thereof, and use thereof | Pending | 25-Nov-2024 | ||
| WO-2026067901-A1 | Topical pharmaceutical composition | Pending | 30-Sep-2024 |
Huilun Pharmaceutical Signals
Huilun Pharmaceutical Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Guizhou Financial Holdings Group | Government | Minority | ||
| Gaoxin Capital | Growth/Expansion | Minority | ||
| Kangcheng Capital | Growth/Expansion | Minority | ||
| Shanghai Tianzi Investment Management | Growth/Expansion | Minority | ||
| Wanlian Tianze Capital Investment | Venture Capital | Minority |
Huilun Pharmaceutical FAQs
-
When was Huilun Pharmaceutical founded?
Huilun Pharmaceutical was founded in 2004.
-
Where is Huilun Pharmaceutical headquartered?
Huilun Pharmaceutical is headquartered in Shanghai, China.
-
What is the size of Huilun Pharmaceutical?
Huilun Pharmaceutical has 1,420 total employees.
-
What industry is Huilun Pharmaceutical in?
Huilun Pharmaceutical’s primary industry is Biotechnology.
-
Is Huilun Pharmaceutical a private or public company?
Huilun Pharmaceutical is a Private company.
-
What is Huilun Pharmaceutical’s current revenue?
The current revenue for Huilun Pharmaceutical is .
-
How much funding has Huilun Pharmaceutical raised over time?
Huilun Pharmaceutical has raised $213M.
-
Who are Huilun Pharmaceutical’s investors?
Guizhou Financial Holdings Group, Gaoxin Capital, Kangcheng Capital, Shanghai Tianzi Investment Management, and Wanlian Tianze Capital Investment are 5 of 12 investors who have invested in Huilun Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process